# Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

> clinical trial · VERIFIED · 2026-07-14

Status: NOT_YET_RECRUITING · Sponsor: Sun Yat-sen University · Condition: ESCC

- Company: Sun Yat-sen University
- Sector: ESCC
- Primary source: https://clinicaltrials.gov/study/NCT07701681

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.